NanoEntek (A039860) Stock Overview
Engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A039860 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NanoEntek, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,095.00 |
| 52 Week High | ₩4,680.00 |
| 52 Week Low | ₩2,885.00 |
| Beta | 0.32 |
| 1 Month Change | -6.78% |
| 3 Month Change | -13.79% |
| 1 Year Change | -7.89% |
| 3 Year Change | -36.64% |
| 5 Year Change | -64.01% |
| Change since IPO | -31.07% |
Recent News & Updates
Recent updates
Investors Shouldn't Be Too Comfortable With NanoEntek's (KOSDAQ:039860) Earnings
Mar 25
Revenues Not Telling The Story For NanoEntek, Inc. (KOSDAQ:039860) After Shares Rise 32%
Oct 10NanoEntek, Inc.'s (KOSDAQ:039860) Revenues Are Not Doing Enough For Some Investors
Aug 06NanoEntek, Inc.'s (KOSDAQ:039860) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Mar 21Should Weakness in NanoenTek, Inc.'s (KOSDAQ:039860) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 14If You Had Bought NanoEnTek (KOSDAQ:039860) Shares A Year Ago You'd Have Earned 48% Returns
Jan 26Calculating The Intrinsic Value Of NanoEnTek, Inc. (KOSDAQ:039860)
Jan 04NanoEnTek Inc.'s (KOSDAQ:039860) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 14Does NanoEnTek's (KOSDAQ:039860) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Shareholder Returns
| A039860 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -5.2% | 2.5% | -3.3% |
| 1Y | -7.9% | 40.4% | 56.1% |
Return vs Industry: A039860 underperformed the KR Life Sciences industry which returned 40.4% over the past year.
Return vs Market: A039860 underperformed the KR Market which returned 56.1% over the past year.
Price Volatility
| A039860 volatility | |
|---|---|
| A039860 Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 10.8% |
| 10% least volatile stocks in KR Market | 2.5% |
Stable Share Price: A039860 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A039860's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 140 | Jin-Hyung Park | www.nanoentek.com |
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company was founded in 1987 and is headquartered in Seoul, South Korea.
NanoEntek, Inc. Fundamentals Summary
| A039860 fundamental statistics | |
|---|---|
| Market cap | ₩117.90b |
| Earnings (TTM) | ₩1.77b |
| Revenue (TTM) | ₩34.10b |
Is A039860 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A039860 income statement (TTM) | |
|---|---|
| Revenue | ₩34.10b |
| Cost of Revenue | ₩13.96b |
| Gross Profit | ₩20.14b |
| Other Expenses | ₩18.37b |
| Earnings | ₩1.77b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 46.46 |
| Gross Margin | 59.05% |
| Net Profit Margin | 5.19% |
| Debt/Equity Ratio | 0% |
How did A039860 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 01:42 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NanoEntek, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seung-Ho Lee | iM Securities |
| NaYeon Kim | Mirae Asset Securities Co., Ltd. |
| null null | Shinhan Investment Corp. |